News Release Details
Verrica Pharmaceuticals Inc. Announces Inclusion in Russell 2000® and Russell 3000® Indexes
"We are very pleased to be included in the
A link to the FTSE Russell website, including a full list of additions and deletions can be found here: https://www.ftserussell.com/research-insights/russell-reconstitution/index-ipo-additions.
Verrica is a pharmaceutical company focused on identifying, developing and commercializing innovative pharmaceutical products for the treatment of skin diseases with significant unmet needs. The company’s lead product candidate, VP-102, is currently being evaluated in two Phase 3 clinical trials for the treatment of molluscum and in a Phase 2 clinical trial for the treatment of common warts.
Cautionary Note Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe”, “expect”, “may”, “plan”, “potential”, “will”, and similar expressions, and are based on Verrica’s current beliefs and expectations. These forward-looking statements include expectations regarding the expansion of Verrica’s visibility in the investor community. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include the risks and uncertainties that are described in Verrica’s Quarterly Report on Form 10-Q for the quarter ended
Chief Financial Officer
484.453.3300 ext. 103
Source: Verrica Pharmaceuticals Inc.